In conclusion, our study shows that SBRT alone can significantly increase the fraction of proliferating CD4+ and CD8+ circulating T-cells, most prominently at the end of treatment and only in the cohort of early-stage NSCLC who received 10 Gy or less per fraction. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.